(Q34625335)

3 August 2017

title

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer (English)

1 reference

triple-negative breast cancer

3 August 2017

main subject

0 references

0 references

14

Funda Meric-Bernstam

1 reference

Ana Maria Gonzalez-Angulo

3 August 2017

1

object named as

Ana M Gonzalez-Angulo

1 reference

3 August 2017

11

Gabriel N Hortobagyi

1 reference

3 August 2017

13

Gordon B Mills

1 reference

3 August 2017

9

Bryan T Hennessy

1 reference

3 August 2017

Kirsten M Timms

2

1 reference

3 August 2017

Shuying Liu

3

1 reference

3 August 2017

Huiqin Chen

4

1 reference

3 August 2017

Jennifer K Litton

5

1 reference

3 August 2017

Jennifer Potter

6

1 reference

3 August 2017

Jerry S Lanchbury

7

1 reference

3 August 2017

Katherine Stemke-Hale

8

1 reference

3 August 2017

Banu K Arun

10

1 reference

3 August 2017

Kim-Anh Do

12

1 reference

3 August 2017

language of work or name

English

0 references

publication date

13 January 2011

1 reference

3 August 2017

published in

Clinical Cancer Research

1 reference

3 August 2017

volume

17

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

1082-1089

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Prognosis of BRCA-associated breast cancer: a summary of evidence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Hallmarks of 'BRCAness' in sporadic cancers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Repeated observation of breast tumor subtypes in independent gene expression data sets

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048924

Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer

7 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21233401

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Expanding the Criteria forBRCAMutation Testing in Breast Cancer Survivors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21233401

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-10-2560

1 reference

3 August 2017

1 reference

3 August 2017

1 reference